Xconomy: Xconomist of the Week: Five Questions About Life Sciences Investing for Dennis Purcell of Aisling Capital
Summary
In the last year or two, life sciences has been a tough sector, especially relative to tech, where you can achieve large valuations in a small amount of time.Given the difficulty in the IPO market and pharmaceutical industry, our theory is that we’re going to have to be able to support these companies longer than we’ve had to in the past.The overriding theme today is not only does your product have to be better than what’s on the market, but it also has to decrease costs to the healthcare system.DP: If you believe in the field of biotechnology, you really have to give your money to somebody who eats, drinks, and sleeps it all day.The individual investor doesn’t have access to the same information and the same experience that a professional mutual fund manager has.
Classifications
AskAI Classifications
LabelsLinked Companies
